Multi-Centre, Randomized, Double-Blind, Placebo-Controlled, Efficacy, and Safety Study of Etripamil Nasal Spray for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia: The NODE-301 Trial

IRB Protocol #: 1801018891

Overview: The purpose of this study is to collect data that may determine whether the study drug, an investigational drug known as etripamil nasal spray, is able to effectively stop an episode of PSVT when taken by a patient to self-treat their PSVT episode. Paroxysmal Supraventricular Tachycardia (PSVT) is an arrhythmia (or heart rhythm disorder) that results in sudden episodes of rapid heart rate, usually at a rate greater than 100 beats per minute. A normal heart rate is about 60 beats per minute. 

This trial is funded by Milestone Pharmaceuticals

To be eligible, patients must:

•   Be older than 18

•   Have been diagnosed with PSVT 

Patients cannot participate if:

•   Diagnosed with hypotension

•   Allergic to verapamil

•   Currently being treated with amiodarone

•   Have a history of severe ventricular arrhythmia

•   Have been diagnosed with congestive heart failure

•   Have suffered a stroke in the past 6 months

Contact:

Dr. James Ip
Principle Investigator
Email: jei9008@med.cornell.edu
Phone: (212) 746-2158
 

Rosa Chu
Research Coordinator
Email: roc2025@med.cornell.edu
Phone: (212) 746-4857